Ignite Creation Date:
2025-12-24 @ 9:55 PM
Ignite Modification Date:
2026-01-10 @ 5:08 PM
Study NCT ID:
NCT06647732
Status:
RECRUITING
Last Update Posted:
2025-03-13
First Post:
2024-10-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Zanubrutinib Plus Rituximab As Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Sponsor:
Sun Yat-sen University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-10-30
Start Date Type:
ACTUAL
Primary Completion Date:
2028-08-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-10-16
First Submit QC Date:
None
Study First Post Date:
2024-10-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-11
Last Update Post Date:
2025-03-13
Last Update Post Date Type:
ACTUAL